Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Abnormal coagulation and enhanced fibrinolysis due to lysinuric protein intolerance associates with bleeds and renal impairment.

Pitkänen HH, Kärki M, Niinikoski H, Tanner L, Näntö-Salonen K, Pikta M, Kopatz WF, Zuurveld M, Meijers JCM, Brinkman HJM, Lassila R.

Haemophilia. 2018 Aug 2. doi: 10.1111/hae.13543. [Epub ahead of print]

PMID:
30070418
2.

Effector T Cell Resistance to Suppression and STAT3 Signaling during the Development of Human Type 1 Diabetes.

Ihantola EL, Viisanen T, Gazali AM, Näntö-Salonen K, Juutilainen A, Moilanen L, Rintamäki R, Pihlajamäki J, Veijola R, Toppari J, Knip M, Ilonen J, Kinnunen T.

J Immunol. 2018 Aug 15;201(4):1144-1153. doi: 10.4049/jimmunol.1701199. Epub 2018 Jul 13.

PMID:
30006377
3.

Circulating CXCR5+PD-1+ICOS+ Follicular T Helper Cells Are Increased Close to the Diagnosis of Type 1 Diabetes in Children With Multiple Autoantibodies.

Viisanen T, Ihantola EL, Näntö-Salonen K, Hyöty H, Nurminen N, Selvenius J, Juutilainen A, Moilanen L, Pihlajamäki J, Veijola R, Toppari J, Knip M, Ilonen J, Kinnunen T.

Diabetes. 2017 Feb;66(2):437-447. doi: 10.2337/db16-0714. Epub 2016 Oct 10.

4.

Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance.

Tanner LM, Kurko J, Tringham M, Aho H, Mykkänen J, Näntö-Salonen K, Niinikoski H, Lukkarinen H.

JIMD Rep. 2017;34:97-104. doi: 10.1007/8904_2016_15. Epub 2016 Oct 26.

5.

Imbalance of plasma amino acids, metabolites and lipids in patients with lysinuric protein intolerance (LPI).

Kurko J, Tringham M, Tanner L, Näntö-Salonen K, Vähä-Mäkilä M, Nygren H, Pöhö P, Lietzen N, Mattila I, Olkku A, Hyötyläinen T, Orešič M, Simell O, Niinikoski H, Mykkänen J.

Metabolism. 2016 Sep;65(9):1361-75. doi: 10.1016/j.metabol.2016.05.012. Epub 2016 May 27.

PMID:
27506743
6.

Clinical, Genetic, and Biochemical Characteristics of Early-Onset Diabetes in the Finnish Population.

Huopio H, Miettinen PJ, Ilonen J, Nykänen P, Veijola R, Keskinen P, Näntö-Salonen K, Vangipurapu J, Raivo J, Stančáková A, Männistö J, Kuulasmaa T, Knip M, Otonkoski T, Laakso M.

J Clin Endocrinol Metab. 2016 Aug;101(8):3018-26. doi: 10.1210/jc.2015-4296. Epub 2016 May 11.

PMID:
27167055
7.

Dysfunction in macrophage toll-like receptor signaling caused by an inborn error of cationic amino acid transport.

Kurko J, Vähä-Mäkilä M, Tringham M, Tanner L, Paavanen-Huhtala S, Saarinen M, Näntö-Salonen K, Simell O, Niinikoski H, Mykkänen J.

Mol Immunol. 2015 Oct;67(2 Pt B):416-25. doi: 10.1016/j.molimm.2015.07.006. Epub 2015 Jul 22.

PMID:
26210182
8.

Urine Beta2-Microglobulin Is an Early Marker of Renal Involvement in LPI.

Kärki M, Näntö-Salonen K, Niinikoski H, Tanner LM.

JIMD Rep. 2016;25:47-55. Epub 2015 Jun 30.

9.

Virus infections among young children--the first year of the INDIS study.

Simonen-Tikka ML, Klemola P, Suomenrinne S, Kaijalainen S, Söderström D, Savolainen-Kopra C, Näntö-Salonen K, Ilonen J, Simell T, Simell O, Roivainen M.

J Med Virol. 2013 Sep;85(9):1678-84. doi: 10.1002/jmv.23625. Epub 2013 Jun 21.

PMID:
23794481
10.

Human rhinoviruses in INDIS-study material-evidence for recovery of viable rhinovirus from fecal specimens.

Savolainen-Kopra C, Simonen-Tikka ML, Klemola P, Blomqvist S, Suomenrinne S, Näntö-Salonen K, Simell O, Roivainen M.

J Med Virol. 2013 Aug;85(8):1466-72. doi: 10.1002/jmv.23593.

PMID:
23765783
11.

[Is it necessary to monitor the cognitive development of a child having diabetes?].

Näntö-Salonen K, Hannonen R.

Duodecim. 2012;128(8):802-9. Review. Finnish.

PMID:
22616371
12.

Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk.

Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, Veijola R, Knip M, Simell O.

Diabetologia. 2012 Jul;55(7):1926-36. doi: 10.1007/s00125-012-2523-3. Epub 2012 Mar 23.

PMID:
22441569
13.

Exploring the transcriptomic variation caused by the Finnish founder mutation of lysinuric protein intolerance (LPI).

Tringham M, Kurko J, Tanner L, Tuikkala J, Nevalainen OS, Niinikoski H, Näntö-Salonen K, Hietala M, Simell O, Mykkänen J.

Mol Genet Metab. 2012 Mar;105(3):408-15. doi: 10.1016/j.ymgme.2011.12.007. Epub 2011 Dec 16.

PMID:
22221392
14.

Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes.

Ryhänen SJ, Härkönen T, Siljander H, Näntö-Salonen K, Simell T, Hyöty H, Ilonen J, Veijola R, Simell O, Knip M.

Diabetes Care. 2011 Jun;34(6):1383-8. doi: 10.2337/dc10-1449. Epub 2011 Apr 22.

15.

Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance.

Niinikoski H, Lapatto R, Nuutinen M, Tanner L, Simell O, Näntö-Salonen K.

JIMD Rep. 2011;1:43-7. doi: 10.1007/8904_2011_15. Epub 2011 Jun 22.

16.

19p13.3 aberrations are associated with dysmorphic features and deviant psychomotor development.

Siggberg L, Olsén P, Näntö-Salonen K, Knuutila S.

Cytogenet Genome Res. 2011;132(1-2):8-15. doi: 10.1159/000320920. Epub 2010 Oct 8.

PMID:
20938164
17.

[Insulin-induced lipoatrophy in children].

Niinikoski H, Näntö-Salonen K, Ruusu P, Kinnala A, Putto-Laurila A, Toppari J, Keskinen P.

Duodecim. 2010;126(11):1328-32. Finnish.

PMID:
20681357
18.

Combined hyperlipidemia in patients with lysinuric protein intolerance.

Tanner LM, Niinikoski H, Näntö-Salonen K, Simell O.

J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S145-50. doi: 10.1007/s10545-010-9050-5. Epub 2010 Feb 23.

PMID:
20177788
19.

From genetic risk awareness to overt type 1 diabetes: parental stress in a placebo-controlled prevention trial.

Goldstein E, Hermann R, Renfors TJ, Näntö-Salonen KM, Korhonen T, Kärkkäinen M, Veijola RK, Knip M, Simell TT, Simell OG.

Diabetes Care. 2009 Dec;32(12):2181-3. doi: 10.2337/dc09-0423. Epub 2009 Sep 14.

20.

[Phenylketonuria].

Niinikoski H, Heikkilä J, Näntö-Salonen K.

Duodecim. 2009;125(10):1069-75. Finnish.

PMID:
19585905
21.

Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes.

Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lähde J, Suortti T, Hakalax J, Simell T, Hyöty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O.

J Exp Med. 2008 Dec 22;205(13):2975-84. doi: 10.1084/jem.20081800. Epub 2008 Dec 15.

22.

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O.

Lancet. 2008 Nov 15;372(9651):1746-55. doi: 10.1016/S0140-6736(08)61309-4. Epub 2008 Sep 22.

PMID:
18814906
23.

Carnitine deficiency and L-carnitine supplementation in lysinuric protein intolerance.

Tanner LM, Näntö-Salonen K, Rashed MS, Kotilainen S, Aalto M, Venetoklis J, Niinikoski H, Huoponen K, Simell O.

Metabolism. 2008 Apr;57(4):549-54. doi: 10.1016/j.metabol.2007.11.019.

PMID:
18328359
24.

Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study.

Niinikoski H, Lagström H, Jokinen E, Siltala M, Rönnemaa T, Viikari J, Raitakari OT, Jula A, Marniemi J, Näntö-Salonen K, Simell O.

Circulation. 2007 Aug 28;116(9):1032-40. Epub 2007 Aug 13.

PMID:
17698729
25.

Nutrient intake in lysinuric protein intolerance.

Tanner LM, Näntö-Salonen K, Venetoklis J, Kotilainen S, Niinikoski H, Huoponen K, Simell O.

J Inherit Metab Dis. 2007 Oct;30(5):716-21. Epub 2007 Jun 21.

PMID:
17588131
26.

Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance.

Tanner LM, Näntö-Salonen K, Niinikoski H, Jahnukainen T, Keskinen P, Saha H, Kananen K, Helanterä A, Metso M, Linnanvuo M, Huoponen K, Simell O.

J Pediatr. 2007 Jun;150(6):631-4, 634.e1.

PMID:
17517249
27.

Long-term oral lysine supplementation in lysinuric protein intolerance.

Tanner LM, Näntö-Salonen K, Niinikoski H, Huoponen K, Simell O.

Metabolism. 2007 Feb;56(2):185-9.

PMID:
17224331
28.

The diagnosis of ectopic focal hyperinsulinism of infancy with [18F]-dopa positron emission tomography.

Hussain K, Seppänen M, Näntö-Salonen K, Adzick NS, Stanley CA, Thornton P, Minn H.

J Clin Endocrinol Metab. 2006 Aug;91(8):2839-42. Epub 2006 May 9.

PMID:
16684819
29.

Poor cognitive development and abdominal pain: Wilson's disease.

Grönlund J, Näntö-Salonen K, Venetoklis J, Holmberg RL, Heinonen A, Ståhlberg MR.

Scand J Gastroenterol. 2006 Mar;41(3):361-4.

PMID:
16497628
30.

Development of overweight in an atherosclerosis prevention trial starting in early childhood. The STRIP study.

Hakanen M, Lagström H, Kaitosaari T, Niinikoski H, Näntö-Salonen K, Jokinen E, Sillanmäki L, Viikari J, Rönnemaa T, Simell O.

Int J Obes (Lond). 2006 Apr;30(4):618-26.

PMID:
16446743
31.

Hazards associated with pregnancies and deliveries in lysinuric protein intolerance.

Tanner L, Näntö-Salonen K, Niinikoski H, Erkkola R, Huoponen K, Simell O.

Metabolism. 2006 Feb;55(2):224-31.

PMID:
16423630
32.

Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography.

Otonkoski T, Näntö-Salonen K, Seppänen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekström K, Guiot Y, Rahier J, Laakso M, Rintala R, Nuutila P, Minn H.

Diabetes. 2006 Jan;55(1):13-8.

33.

Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.

Autti-Rämö I, Mäkelä M, Sintonen H, Koskinen H, Laajalahti L, Halila R, Kääriäinen H, Lapatto R, Näntö-Salonen K, Pulkki K, Renlund M, Salo M, Tyni T.

Acta Paediatr. 2005 Aug;94(8):1126-36.

PMID:
16188860
34.

Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment.

Hero M, Jänne OA, Näntö-Salonen K, Dunkel L, Raivio T.

J Clin Endocrinol Metab. 2005 Sep;90(9):5141-5. Epub 2005 Jun 28.

PMID:
15985486
35.

Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.

Cuesta-Muñoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Näntö-Salonen K, Rahier J, López-Enriquez S, García-Gimeno MA, Sanz P, Soriguer FC, Laakso M.

Diabetes. 2004 Aug;53(8):2164-8.

36.

Epitopes recognized by CBV4 responding T cells: effect of type 1 diabetes and associated HLA-DR-DQ haplotypes.

Marttila J, Hyöty H, Näntö-Salonen K, Simell O, Ilonen J.

Virology. 2004 Feb 5;319(1):27-35.

37.

Oral supplementation corrects plasma lysine concentrations in lysinuric protein intolerance.

Lukkarinen M, Näntö-Salonen K, Pulkki K, Aalto M, Simell O.

Metabolism. 2003 Jul;52(7):935-8.

PMID:
12870174
38.

Peripheral nervous system in gyrate atrophy of the choroid and retina with hyperornithinemia.

Peltola KE, Jääskeläinen S, Heinonen OJ, Falck B, Näntö-Salonen K, Heinänen K, Simell O.

Neurology. 2002 Sep 10;59(5):735-40.

PMID:
12221166
39.

[The mystery of a red buttock].

Nänto-Salonen K.

Duodecim. 1999;115(6):681,683. Finnish. No abstract available.

PMID:
11892613
40.

Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children.

Järvisalo MJ, Jartti L, Näntö-Salonen K, Irjala K, Rönnemaa T, Hartiala JJ, Celermajer DS, Raitakari OT.

Circulation. 2001 Dec 11;104(24):2943-7.

PMID:
11739310
41.

Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase.

Peltola KE, Näntö-Salonen K, Heinonen OJ, Jääskeläinen S, Heinänen K, Simell O, Nikoskelainen E.

Ophthalmology. 2001 Apr;108(4):721-9.

PMID:
11297489
42.

Oral lysine feeding in gyrate atrophy with hyperornithinaemia--a pilot study.

Peltola K, Heinonen OJ, Näntö-Salonen K, Pulkki K, Simell O.

J Inherit Metab Dis. 2000 Jun;23(4):305-7. No abstract available.

PMID:
10896280
43.

Effect of lysine infusion on urea cycle in lysinuric protein intolerance.

Lukkarinen M, Näntö-Salonen K, Pulkki K, Mattila K, Simell O.

Metabolism. 2000 May;49(5):621-5.

PMID:
10831173
44.

Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets.

Tyynismaa H, Kaitila I, Näntö-Salonen K, Ala-Houhala M, Alitalo T.

Hum Mutat. 2000 Apr;15(4):383-4.

PMID:
10737991
45.

Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia.

Valtonen M, Näntö-Salonen K, Jääskeläinen S, Heinänen K, Alanen A, Heinonen OJ, Lundbom N, Erkintalo M, Simell O.

J Inherit Metab Dis. 1999 Dec;22(8):855-66.

PMID:
10604138
46.

Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia.

Heinänen K, Näntö-Salonen K, Komu M, Erkintalo M, Alanen A, Heinonen OJ, Pulkki K, Nikoskelainen E, Sipilä I, Simell O.

Eur J Clin Invest. 1999 Dec;29(12):1060-5.

PMID:
10583455
47.

Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia.

Nänto-Salonen K, Komu M, Lundbom N, Heinänen K, Alanen A, Sipilä I, Simell O.

Neurology. 1999 Jul 22;53(2):303-7.

PMID:
10430418
48.

Serum type III procollagen in children with type I hereditary tyrosinemia.

Pitkänen S, Salo MK, Vettenranta K, Näntö-Salonen K, Heikinheimo M.

J Pediatr Gastroenterol Nutr. 1999 Jul;29(1):38-41.

PMID:
10400101
49.

Muscle creatine phosphate in gyrate atrophy of the choroid and retina with hyperornithinaemia--clues to pathogenesis.

Heinänen K, Näntö-Salonen K, Komu M, Erkintalo M, Heinonen OJ, Pulkki K, Valtonen M, Nikoskelainen E, Alanen A, Simell O.

Eur J Clin Invest. 1999 May;29(5):426-31.

PMID:
10354199
50.

Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusion in a pubertal boy.

Näntö-Salonen K, Koskinen P, Sonninen P, Toppari J.

Acta Paediatr. 1999 Jan;88(1):29-33.

PMID:
10090543

Supplemental Content

Loading ...
Support Center